Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

Teva (TEVA) and Sanofi (SNY) announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A, which showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis, or UC, and Crohn’s disease, or CD, that initially responded to the induction phase. UC and CD are the two most common forms of inflammatory bowel disease, or IBD. These longer duration data reinforce the efficacy from the RELIEVE UCCD phase 2b induction study, which demonstrated that patients achieved clinically meaningful response with duvakitug compared to placebo at week 14. At week 44 of the maintenance period, in UC, 58% of the 900 mg patients and 47% of the 450 mg patients treated with duvakitug achieved the primary endpoint of clinical remission. In CD, 55% of the 900 mg and 41% of the 450 mg dosage legs of patients treated with duvakitug achieved the primary endpoint of endoscopic response. In both UC and CD, consistent benefits were observed across additional efficacy endpoints. Both doses of duvakitug were well tolerated.